Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Recent & Breaking News (NDAQ:MBRX)

Moleculin Provides Update on Coronavirus Drug Development

PR Newswire May 27, 2020

Nasdaq Halts Moleculin Biotech Inc.

GlobeNewswire May 18, 2020

Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information

PR Newswire May 18, 2020

Moleculin Provides Additional Comments Regarding Trading Halt

PR Newswire May 11, 2020

Investor Alert: Kaplan Fox Investigates Moleculin Biotech, Inc.

PR Newswire May 8, 2020

Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020

PR Newswire May 8, 2020

Moleculin Announces Trading Halt

PR Newswire May 4, 2020

Moleculin to Speak on COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference

PR Newswire April 29, 2020

WPD Pharmaceutical's Annamycin Drug Approved for Accelerated European Clinical Trial

GlobeNewswire April 29, 2020

Moleculin Approved to Accelerate European Clinical Trial

PR Newswire April 28, 2020

WPD Pharmaceuticals' Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity

GlobeNewswire April 23, 2020

Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team

PR Newswire April 22, 2020

WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences

GlobeNewswire April 21, 2020

Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing

PR Newswire April 20, 2020

Moleculin to Host Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate Today

PR Newswire April 16, 2020

Moleculin Announces Leading Virologist Joins Development Team

PR Newswire April 15, 2020

Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate

PR Newswire April 14, 2020

WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%

GlobeNewswire April 9, 2020

Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100%

PR Newswire April 8, 2020

Moleculin Announces Additional Positive Safety Data in EU AML Trial

PR Newswire April 2, 2020